Aerie Pharmaceuticals Inc (NASDAQ: AERI) shares were seen up over 29 percent Thursday after the company reported positive Phase III trial data on its glaucoma treatment candidate, Roclatan. According to the company, Roclatan achieved the primary efficacy endpoint in demonstrating superiority over both latanoprost and Rhopressa.
Investors cheered the positive news, but Aerie may have even more upside in the months ahead, H.C. Wainwright analyst Corey Davis said.
“Amidst reporting broad success in its Phase 3 MERCURY 2 trial of Roclatan vs. its Rhopressa and latanoprost subcomponents at all 9 observed timepoints, responder analysis indicating 32 percent of patients reached IOPs below 14 mmHg by the end of the 90-day treatment period was particularly impressive in our view, as this is likely the most convincing data for prescribing physicians leading up to NDA filing for Roclatan in IH 18,” Davis said.
The binary risk involved in the Roclatan Phase III study has now been eliminated, leaving the door open for Aerie stock to soar, Davis said.
Between now and the expected NDA filing for Roclatan in early 2018, the only potential meaningful stock catalyst remaining is the 12-month safety and efficacy update from the MERCURY 1 trial, which Davis expects will come in Q3 of this year. Based on the string data Roclatan has demonstrated so far, Davis said it is unlikely the long-term study will reveal any potential concerns.
H.C. Wainwright is projecting…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
